Our Team

The Canna Capital team is composed of experts with years of experience in the study of medical cannabis and its positive effects on human health, as well as legal experts with extensive experience in the medical arena and investment experts with notable global experience.

Keith Edelman brings extensive commercial experience including having completed over £2 billion of M&A transactions. Keith is currently chairman of Revolution Bars Group Plc and Jewellery Bullion Quarter Ltd, the senior non-executive director of Headlam Group Plc and a non-executive director of E20 LLP. ​In his executive career he was a director of Ladbroke Group Plc, Managing Director at Carlton Communications Plc, and chief executive officer of Storehouse Plc. His last executive appointment, which ended in 2008 was Managing Director of Arsenal Holdings Plc where he was responsible for the move from Highbury to the Emirates Stadium. Since 2009, Keith has held a number of non-executive roles including Safestore Plc, Superdry Plc, London Legacy Development Corporation, Altitude Group Plc and Thorntons Plc.

Adhum is an entrepreneur with board level experience across a range of sectors specializing in investment capital raising and strategic development. He is currently Chief Strategy Officer for Imperial Corporate Capital plc a UK based property developer establishing strategic plans and collaborating with multiple staff from the leadership teams executives and the board. Adhum’s experience includes assisting investment and capital fundraising operations coordinating strategic development identifying profitable business opportunities leading operations to accelerate revenue growth and stimulate top organization performance. Adhum previously worked for Allianz International Holdings Ltd, a UAE based private equity company where he assisted with structuring analyzing and managing property acquisitions. Adhum has experience in overseeing operations within the cannabis space developing and implementing competitive strategies to accelerate business growth and expand footprints.
He supervised the build of a European hemp cultivation farm and extraction facility as well as managing the application process for growing cultivation and extraction licenses.

After pursuing post-graduate studies in General Medicine and research in biochemical neuropsychopharmacology at The Royal Post-Graduate Medical School, Dr. Ungar was in practice as a General Physician at The Princess Grace Hospital. Jointly with Dr. Raymond Prudo, Dr. Ungar founded a start-up company, The Doctors Laboratory PLC, a general pathology laboratory that introduced a new paradigm in service provision for clinicians and pharmaceutical organizations throughout the United Kingdom and abroad. During his tenure as Chairman and Board Director, The Doctors Laboratory PLC grew substantially and was sold to Sonic Healthcare in 2002. Currently, he is a Director of a NASDAQ quoted biopharmaceutical company creating drugs for acute and chronic orphan inflammatory diseases. Dr. Ungar qualified in medicine, with additional qualifications in medical biochemistry at the Royal Free Hospital, London, and was admitted as a member to The Royal College of Physicians. Dr. Ungar is a Life Fellow of The Royal Society of Medicine and is a founder and former Vice-President of The Independent Doctors Federation.

Toby Shillito has been designing and operating licensed facilities to cultivate Medical Cannabis in Europe over the past 7 years, assessing the value of many technological innovations in this space. He established the Cannabis Industry Council’s Corporate Responsibility Group in Q2 of this year.He has also founded iGeneration.Life, a pharmaceutical company pursuing Medicines and Healthcare products Regulatory Agency (MHRA) licenses for cannabis based medicinal products in the UK. Toby’s vast experience in the medical cannabis industry enables him to identify business models that are likely to succeed in the post-prohibition era, as well as assist cannabis companies to comply with their social and environmental responsibilities.

Tom Price was a corporate financier for over 30 years and has held corporate finance roles advising growing businesses across a broad range of sectors. From 2018 to 2019, he worked with Arden Partners PLC as corporate finance director. From 2016 to 2018, he served as corporate finance director with Northland Capital Partners Limited. From 2013 to 2016, he was head of corporate finance with ZAI Corporate Finance Limited. From 2009 to 2012, he held senior positions at Westhouse Securities including those of corporate finance director, chief operating officer, acting chief executive officer and PLC board director. From 2002 to 2009, he worked as corporate finance director at Evolution Securities. From 1990 to 2002 he held the positions of corporate financier and director with Beeson Gregory Limited. He a non-executive director of AIM-quoted Glantus Holdings plc and he oc​is also treasurer and arts adviser to Cockayne – Grants for the Arts and a trustee of the Braintree Museum Trust.

Dr. Peter Feldschreiber is dually qualified as a barrister and physician. He specialises in medical and healthcare law including medical products liability, pharmaceutical and medical devices regulatory law, clinical negligence and personal injury and medically related employment litigation. Casework includes the Aspirin Reyes Syndrome product liability litigation, Atomic Veterans Litigation, the morning after pill litigation, the Seroquel litigation, Foetal Anti- convulsant Syndrome Litigation, Cochlear Implants and Cardiac Stent Litigations and judicial review and references to the ECJ on pharmaceutical regulatory issues. He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Medicines and Healthcare products Regulatory Agency, Department of Health. Dr Feldschreiber is General Editor of The Law and Regulation of Medicines (Oxford University Press) and is Consultant Editor for the Volume on Medical Products for Halsburys Laws of England and the Lexis Nexis series on updates of UK and European Law. He is co-author of the chapter on the regulation of healthcare products in Butterworths Healthcare Law and Practice. Peter is also the Visiting Senior Lecturer in Pharmaceutical Science at Kings College London. He is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury. He has also published extensively on the law of causation and European regulatory procedure. He has published research into the repair of DNA following ionising radiation whilst working at the Institute of Cancer Research. He is also a member of the Expert Witness Institute. 

After qualifying in medicine from London’s St Bartholomew’s Hospital Medical School in 1980, Angela trained in adult haematology, subsequently specialising in paediatric haematology. She worked as a consultant at the Royal Hospital for Sick Children, Edinburgh, where she is currently working as part of the COVID-19 response. She was a fellow in molecular biology at University College London, and was awarded a PhD. In addition, Angela was Director of the haemophilia centre at the city’s Royal Infirmary until June 2017. She has played a lead role in the regulation of medicines at a National, European and International level since 2002 and was vice chair of the UK government’s Commission on Human Medicines until December 2018. Angela Thomas is former president of the British Society for Haematology and was appointed honorary professor in the College of Medicine and Veterinary Medicine, University of Edinburgh, in August 2015. She has a particular interest in congenital and acquired bleeding disorders, particularly in the context of non-accidental injury, and has published and lectured extensively in this area. Angela was awarded an OBE for her services to the Regulation of Medicines for the protection and promotion of Public Health in the 2018 New Year’s Honours List. She continues to work for the licensing authority (MHRA) on the efficacy and safety of medicines.

Experienced Director with a record of discovery of new therapeutics for rare diseases and gaining market authorisation in Europe and USA for medicinal products in neonates, asthma and COPD. Strong professional skills in Pharmaceutics, Biomarkers, Translational Medicine, Medical Devices, and Vaccines. Led multinational collaborative programmes in the European Framework V and Innovative Medicines Initiatives.